Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
Technology appraisal guidance
Reference number: TA914
Published:
Tools and resources
Tools and resources to help you put the guidance into practice.